| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2022 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | R41AI167146 | Development of an improved intranasal vaccine against influenza | 000 | 1 | NIH | 2/13/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $986,133 ) |
| | 2024 | 2024 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | U44AI152995 | A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine | 001 | 2 | NIH | 7/22/2024 | $985,958 |
| | 2024 | 2024 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | U44AI152995 | A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine | 002 | 2 | NIH | 7/29/2024 | $175 |
| | 2024 | 2020 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | U44AI152995 | A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine | 000 | 1 | NIH | 11/16/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $825,048 ) |
| | 2023 | 2023 | NAJIT TECHNOLOGIES INC | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | U44AI145791 | A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine | 000 | 4 | NIH | 7/12/2023 | $825,048 |
| | 2023 | 2019 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | R44AI128990 | Development of an H2O2-inactivated chikungunya virus vaccine | 000 | 3 | NIH | 11/22/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,272,769 ) |
| | 2022 | 2022 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | R41AI167146 | Development of an improved intranasal vaccine against influenza | 001 | 1 | NIH | 9/9/2022 | $275,107 |
| | 2022 | 2022 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | R41AI167146 | Development of an improved intranasal vaccine against influenza | 001 | 1 | NIH | 9/9/2022 | -$275,107 |
| | 2022 | 2022 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | R41AI167146 | Development of an improved intranasal vaccine against influenza | 000 | 1 | NIH | 7/29/2022 | $275,107 |
| | 2022 | 2022 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | U44AI145791 | A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine | 001 | 3 | NIH | 6/27/2022 | $997,662 |
| | 2022 | 2020 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | U44AI152995 | A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine | 000 | 1 | NIH | 1/7/2022 | $0 |
| | 2022 | 2019 | NAJIT TECHNOLOGIES INC | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | U44AI145791 | A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine | 000 | 1 | NIH | 12/7/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $999,652 ) |
| | 2021 | 2021 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | U44AI145791 | A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine | 003 | 2 | NIH | 7/26/2021 | $0 |
| | 2021 | 2021 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | U44AI145791 | A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine | 002 | 2 | NIH | 7/2/2021 | $999,652 |
| | 2021 | 2020 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | R44AI079898 | Development of a Yellow Fever Vaccine for a Vulnerable Population | 000 | 8 | NIH | 9/10/2021 | $0 |
| | 2021 | 2019 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | R43IP001130 | Optimization of vaccine antigen for the development of improved influenza | 02 | 1 | CDC | 12/1/2020 | $0 |
| | 2021 | 2019 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | R44AI128990 | Development of an H2O2-inactivated chikungunya virus vaccine | 000 | 3 | NIH | 2/2/2021 | $0 |
| | 2021 | 2019 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | U44AI145791 | A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine | 000 | 1 | NIH | 2/5/2021 | $0 |
| | 2021 | 2019 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | U44AI145791 | A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine | 001 | 1 | NIH | 7/2/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,287,914 ) |
| | 2020 | 2020 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | R44AI079898 | Development of a Yellow Fever Vaccine for a Vulnerable Population | 000 | 8 | NIH | 1/23/2020 | $997,494 |
| | 2020 | 2020 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | U44AI152995 | A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine | 000 | 1 | NIH | 6/30/2020 | $290,420 |
| | 2020 | 2019 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | R43IP001130 | Optimization of vaccine antigen for the development of improved influenza | 01 | 1 | CDC | 10/29/2019 | $0 |
| | 2020 | 2019 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | R44AI128990 | Development of an H2O2-inactivated chikungunya virus vaccine | 000 | 3 | NIH | 2/27/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $2,502,315 ) |
| | 2019 | 2019 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | R43IP001130 | Optimization of vaccine antigen for the development of improved influenza | 00 | 1 | CDC | 8/1/2019 | $224,171 |
| | 2019 | 2019 | NAJIT TECHNOLOGIES, INC. | 505 NW 185TH AVE | BEAVERTON | OR | 97006-3448 | WASHINGTON | USA | R44AI079898 | Development of a Yellow Fever Vaccine for a Vulnerable Population | 000 | 7 | NIH | 1/16/2019 | $996,895 |
| | 2019 | 2019 | NAJIT TECHNOLOGIES, INC. | 505 NW 185TH AVE | BEAVERTON | OR | 97006-3448 | WASHINGTON | USA | R44AI128990 | Development of an H2O2-inactivated chikungunya virus vaccine | 000 | 3 | NIH | 2/7/2019 | $989,109 |
| | 2019 | 2019 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | R44AI128990 | Development of an H2O2-inactivated chikungunya virus vaccine | 001 | 3 | NIH | 9/12/2019 | $0 |
| | 2019 | 2019 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | U44AI145791 | A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine | 000 | 1 | NIH | 6/14/2019 | $292,140 |
| | 2019 | 2016 | NAJIT TECHNOLOGIES, INC. | 15232 NW GREENBRIER PKWY | BEAVERTON | OR | 97006-5764 | WASHINGTON | USA | R41AI122462 | Development of a novel platform to enhance intracellular bioavailability of antisense morpholino oligomers | 000 | 1 | NIH | 11/1/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $2,242,955 ) |
| | 2018 | 2018 | NAJIT TECHNOLOGIES, INC. | 505 NW 185TH AVE | BEAVERTON | OR | 97006-3448 | WASHINGTON | USA | R44AI079898 | Development of a Yellow Fever Vaccine for a Vulnerable Population | 000 | 6 | NIH | 1/25/2018 | $992,041 |
| | 2018 | 2018 | NAJIT TECHNOLOGIES, INC. | 505 NW 185TH AVE | BEAVERTON | OR | 97006-3448 | WASHINGTON | USA | R44AI079898 | Development of a Yellow Fever Vaccine for a Vulnerable Population | 001 | 6 | NIH | 7/25/2018 | $256,073 |
| | 2018 | 2018 | NAJIT TECHNOLOGIES, INC. | 505 NW 185TH AVE | BEAVERTON | OR | 97006-3448 | WASHINGTON | USA | R44AI128990 | Development of an H2O2-inactivated chikungunya virus vaccine | 000 | 2 | NIH | 2/16/2018 | $994,841 |
|
| Issue Date FY: 2017 ( Subtotal = $999,652 ) |
| | 2017 | 2017 | NAJIT TECHNOLOGIES, INC. | 505 NW 185TH AVE | BEAVERTON | OR | 97006-3448 | WASHINGTON | USA | R44AI128990 | Development of an H2O2-inactivated chikungunya virus vaccine | 000 | 1 | NIH | 2/28/2017 | $999,652 |
| | 2017 | 2013 | NAJIT TECHNOLOGIES, INC. | 505 NW 185TH AVE | BEAVERTON | OR | 97006-3448 | WASHINGTON | USA | R44AI079898 | Development of a Yellow Fever Vaccine for a Vulnerable Population | 000 | 5 | NIH | 4/13/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $318,591 ) |
| | 2016 | 2016 | NAJIT TECHNOLOGIES INC | 2611 SOUTHWEST 3RD AVENUE | PORTLAND | OR | 97201-4957 | MULTNOMAH | USA | R41AI122462 | Development of a novel platform to enhance intracellular bioavailability of antisense morpholino oligomers | 000 | 1 | NIH | 7/27/2016 | $318,591 |
| | 2016 | 2013 | NAJIT TECHNOLOGIES INC | 2611 SOUTHWEST 3RD AVENUE | PORTLAND | OR | 97201 | MULTNOMAH | USA | R44AI079898 | Development of a Yellow Fever Vaccine for a Vulnerable Population | 000 | 5 | NIH | 12/2/2015 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = $0 ) |
| | 2015 | 2013 | NAJIT TECHNOLOGIES INC | 2611 SOUTHWEST 3RD AVENUE | PORTLAND | OR | 97201 | MULTNOMAH | USA | R44AI079898 | Development of a Yellow Fever Vaccine for a Vulnerable Population | 000 | 5 | NIH | 1/9/2015 | $0 |
|
| Issue Date FY: 2013 ( Subtotal = $994,154 ) |
| | 2013 | 2013 | NAJIT TECHNOLOGIES INC | 2611 SOUTHWEST 3RD AVENUE | PORTLAND | OR | 97201-4957 | MULTNOMAH | USA | R44AI079898 | Development of a Yellow Fever Vaccine for a Vulnerable Population | 000 | 5 | NIH | 12/24/2012 | $994,154 |
|
|
